# PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

> **NCT00819780** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 285 (actual)

## Conditions studied

- Colon Cancer
- Colorectal Cancer
- Rectal Cancer
- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Panitumumab
- **DRUG:** Bevacizumab
- **DRUG:** mFOLFOX6

## Key facts

- **NCT ID:** NCT00819780
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-24
- **Primary completion:** 2012-05-30
- **Final completion:** 2016-07-07
- **Target enrollment:** 285 (ACTUAL)
- **Last updated:** 2022-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00819780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00819780, "PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00819780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*